Trial 'should define the potential renoprotective effect' of Invokana

2 February 2017

The rationale and design of a pivotal investigational study on the potential beneficial effects of the diabetes drug Invokana (canagliflozin) on kidney disease progression have been published.

Invokana, the most prescribed sodium glucose co-transporter 2 (SGLT2) inhibitor in the USA, was approved in March 2013 and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, which commonly causes kidney damage in patients.

The CANVAS-R trial is designed to test the effect of Invokana, which belongs to Janssen, part of US healthcare giant Johnson & Johnson (NYSE: JNJ), in slowing the decline of kidney function in type 2 diabetes patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK